GlassScriptPhysician profile
Hemanth Hampole
NPI 1295042471
$6,758.69
in general payments reported to CMS, 2019-2025
35 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $651 · 2021: $825 · 2022: $772 · 2023: $1,133 · 2024: $1,697 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,902 · Travel and Lodging: $296 · Education: $93.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.93 |
| Travel and Lodging | $296.27 |
| Education | $93.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,294.37 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $717.10 | 2020-2025 | Acthar, Terlivaz |
| Medtronic, INC. | $610.33 | 2023-2024 | Ellipsys Vascular Access System |
| Novartis Pharmaceuticals Corporation | $440.93 | 2023-2025 | |
| Vifor Pharma, INC. | $401.51 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $393.70 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $329.40 | 2021-2025 | |
| Amgen INC. | $309.88 | 2020-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $300.35 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $276.57 | 2020-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $227.60 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $158.59 | 2022-2025 | Filspari |
| Ani Pharmaceuticals, INC. | $156.27 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.17 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $121.60 | 2019-2025 | Auryxia, Vafseo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $103.64 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $81.31 | 2020-2024 | Rayaldee |
| Ardelyx, INC. | $80.00 | 2024-2025 | Ibsrela |
| Medline Industries LP | $64.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $58.53 | 2021-2023 | Xarelto |
| Angiodynamics, INC. | $56.98 | 2020 | |
| Merck Sharp & Dohme LLC | $53.82 | 2023 | Dificid, Prevymis |
| Abbott Laboratories | $50.76 | 2024 | Diamondback Peripheral |
| Lilly USA, LLC | $47.58 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $46.24 | 2023-2025 | Benlysta, Shingrix |
| Fresenius USA Marketing, INC. | $43.98 | 2020-2023 | Velphoro |
| Cook Medical LLC | $36.30 | 2020-2024 | Tornado |
| Philips North America LLC | $28.09 | 2022 | |
| Novo Nordisk INC | $25.10 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.29 | 2022 | |
| Boston Scientific Corporation | $20.19 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.88 | 2025 | |
| Genzyme Corporation | $16.96 | 2021 | |
| Argon Medical Devices, INC. | $16.53 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemanth Hampole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.